Ngala R A, O'Dowd J, Wang S J, Agarwal A, Stocker C, Cawthorne M A, Arch J R S
Clore Laboratory, University of Buckingham, Buckingham, UK.
Br J Pharmacol. 2008 Oct;155(3):395-406. doi: 10.1038/bjp.2008.244. Epub 2008 Jun 16.
Picomolar concentrations of the beta3-adrenoceptor agonist BRL37344 stimulate 2-deoxyglucose uptake in soleus muscle via undefined receptors. Higher concentrations alter uptake, apparently via beta2-adrenoceptors. Effects of BRL37344 and beta2-adrenoceptor agonists are compared.
Mouse soleus muscles were incubated with 2-deoxy[1-(14)C]-glucose, [1-(14)C]-palmitate or [2-(14)C]-pyruvate, and BRL37344, beta2-adrenoceptor agonists and selective beta-adrenoceptor antagonists. Formation of 2-deoxy[1-(14)C]-glucose-6-phosphate or (14)CO2 was measured. 2-Deoxy[1-(14)C]-glucose uptake and beta-adrenoceptor mRNA were measured in C2C12 cells.
10 pM BRL37344, 10 pM clenbuterol and 100 pM salbutamol stimulated 2-deoxyglucose uptake in soleus muscle by 33-54%. The effect of BRL37344 was prevented by 1 microM atenolol but not by 300 nM CGP20712A or IC3118551, or 1 microM SR59230A; that of clenbuterol was prevented by ICI118551 but not atenolol. 10 nM BRL37344 stimulated 2-deoxyglucose uptake, whereas 100 nM clenbuterol and salbutamol inhibited uptake. These effects were blocked by ICI118551. Similar results were obtained in C2C12 cells, in which only beta2-adrenoceptor mRNA could be detected by RT-PCR. 10 nM BRL37344 and 10 pM clenbuterol stimulated muscle palmitate oxidation. In the presence of palmitate, BRL37344 no longer stimulated 2-deoxyglucose uptake and the effect of clenbuterol was not significant.
Stimulation of glucose uptake by 10 pM BRL37344 and clenbuterol involves different atypical pharmacologies. Nanomolar concentrations of BRL37344 and clenbuterol, probably acting via beta2-adrenoceptors, have opposite effects on glucose uptake. The agonists preferentially stimulate fat rather than carbohydrate oxidation, but stimulation of endogenous fat oxidation cannot explain why 100 nM clenbuterol inhibited 2-deoxyglucose uptake.
皮摩尔浓度的β3肾上腺素能受体激动剂BRL37344通过未知受体刺激比目鱼肌对2-脱氧葡萄糖的摄取。更高浓度时则明显通过β2肾上腺素能受体改变摄取。比较了BRL37344和β2肾上腺素能受体激动剂的作用。
将小鼠比目鱼肌与2-脱氧[1-(14)C]-葡萄糖、[1-(14)C]-棕榈酸酯或[2-(14)C]-丙酮酸以及BRL37344、β2肾上腺素能受体激动剂和选择性β肾上腺素能拮抗剂一起孵育。测定2-脱氧[1-(14)C]-葡萄糖-6-磷酸或(14)CO2的生成。在C2C12细胞中测定2-脱氧[1-(14)C]-葡萄糖摄取和β肾上腺素能受体mRNA。
10 pM的BRL37344、10 pM的克仑特罗和100 pM的沙丁胺醇使比目鱼肌中2-脱氧葡萄糖摄取增加33%-54%。1 μM阿替洛尔可阻断BRL37344 的作用,但300 nM的CGP20712A、IC3118551或1 μM的SR59230A则不能;ICI118551可阻断克仑特罗的作用,而阿替洛尔则不能。10 nM的BRL37344刺激2-脱氧葡萄糖摄取,而100 nM的克仑特罗和沙丁胺醇则抑制摄取。这些作用可被ICI118551阻断。在C2C12细胞中也得到了类似结果,通过RT-PCR仅能检测到β2肾上腺素能受体mRNA。10 nM的BRL37344和10 pM的克仑特罗刺激肌肉棕榈酸氧化。在有棕榈酸存在时,BRL37344不再刺激2-脱氧葡萄糖摄取,克仑特罗的作用也不显著。
10 pM的BRL37344和克仑特罗对葡萄糖摄取的刺激涉及不同的非典型药理学机制。纳摩尔浓度的BRL37344和克仑特罗可能通过β2肾上腺素能受体起作用,对葡萄糖摄取有相反的影响。这些激动剂优先刺激脂肪而非碳水化合物氧化,但内源性脂肪氧化的刺激并不能解释为什么100 nM的克仑特罗会抑制2-脱氧葡萄糖摄取。